arrow

From NeuroLex

Jump to: navigation, search



Bevacizumab

Name: Bevacizumab
Description: A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Pharmacology: Bevacizumab prevents or reduces the formation of blood vessels (angiogenesis) thereby preventing or reducing metatstatic disease progressing. Bevacizumab binds VEGF and prevents vascular endothelial growth and endothelial cell proliferation. Mechanism of action: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. This prevents blood vessel growth. Drug type: Approved. Biotech. Investigational. Drug category: Antiangiogenesis Agents. Antineoplastic Agents
Synonym(s): Avastin, R-435, antiVEGF, bevacizumab, Avastin, Avastin (Genentech Inc)
Has role: Drug
Super-category: Molecular entity
URL: http://www.drugbank.ca/drugs/DB00112
*Id: DB00112
Related to: Vascular endothelial growth factor A, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c
Link to OWL / RDF: Download this content as OWL/RDF


Contributors

Ccdbuser, Nifbot2



bookmark

*Neurolex imports many terms from existing community ontologies, e.g., the Gene Ontology. We try to re-use the original identifier when possible and often import content from the original ontology. However, Neurolex is a dynamic site and any content beyond the identifier should not be presumed to reflect the content or views of the source ontology. Users should consult with the authoritative source for each ontology for current information.

Facts about BevacizumabRDF feed
Commenttaken from DrugBank
CuratorAb  +
DefiningCitationhttp://www.drugbank.ca/drugs/DB00112  +
DefinitionA recombinant humanized monoclonal IgG1 an A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Pharmacology: Bevacizumab prevents or reduces the formation of blood vessels (angiogenesis) thereby preventing or reducing metatstatic disease progressing. Bevacizumab binds VEGF and prevents vascular endothelial growth and endothelial cell proliferation. Mechanism of action: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. This prevents blood vessel growth. Drug type: Approved. Biotech. Investigational. Drug category: Antiangiogenesis Agents. Antineoplastic Agents angiogenesis Agents. Antineoplastic Agents
Has roleDrug  +
IdDB00112  +
LabelBevacizumab  +
ModifiedDate14 April 2014  +
RelatedToVascular endothelial growth factor A  +, High affinity immunoglobulin gamma Fc receptor I  +, Low affinity immunoglobulin gamma Fc region receptor III-B  +, Complement C1r subcomponent  +, Complement C1q subcomponent subunit A  +, Complement C1q subcomponent subunit B  +, Complement C1q subcomponent subunit C  +, Low affinity immunoglobulin gamma Fc region receptor III-A  +, Low affinity immunoglobulin gamma Fc region receptor II-a  +, Low affinity immunoglobulin gamma Fc region receptor II-b  +, and Low affinity immunoglobulin gamma Fc region receptor II-c  +
SuperCategoryMolecular entity  +
SynonymAvastin  +, R-435  +, antiVEGF  +, bevacizumab  +, and Avastin (Genentech Inc)  +